|
1
|
Treuner J, Feine U, Niethammer D,
Muller-Schaumburg W, Meinke J, Eibach E, Dopfer R, Klingebiel T and
Grumbach S: Scintigraphic imaging of neuroblastoma with
[131-I]iodobenzylguanidine. Lancet. 1:333–334. 1984.
|
|
2
|
Matthay KK, Yanik G, Messina J, Quach A,
Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS,
Hawkins RA and Maris JM: Phase II study on the effect of disease
sites, age, and prior therapy on response to
iodine-131-metaiodobenzylguanidine therapy in refractory
neuroblastoma. J Clin Oncol. 25:1054–1060. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Seeger RC, Brodeur GM, Sather H, Dalton A,
Siegel SE, Wong KY and Hammond D: Association of multiple copies of
the N-myc oncogene with rapid progression of neuroblastomas. New
Engl J Med. 313:1111–1116. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fredlund E, Ringner M, Maris JM and
Pahlman S: High Myc pathway activity and low stage of neuronal
differentiation associate with poor outcome in neuroblastoma. Proc
Natl Acad Sci USA. 105:14094–14099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takahashi K, Tanabe K, Ohnuki M, Narita M,
Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem
cells from adult human fibroblasts by defined factors. Cell.
131:861–872. 2007. View Article : Google Scholar
|
|
6
|
Ikegaki N, Shimada H, Fox AM, Regan PL,
Jacobs JR, Hicks SL, Rappaport EF and Tang XX: Transient treatment
with epigenetic modifiers yields stable neuroblastoma stem cells
resembling aggressive large-cell neuroblastomas. Proc Natl Acad Sci
USA. 110:6097–6102. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ikegaki N, Regan PL, Hicks SL, Maloney N
and Tang XX: Regulation of MYCN stability by reactive oxygen
species in neuroblastoma. Cancer Res. 71(Suppl 1): Abstract LB-142.
2011. View Article : Google Scholar
|
|
8
|
Tang XX, Zhao H, Robinson ME, Cohen B,
Cnaan A, London W, Cohn SL, Cheung NK, Brodeur GM, Evans AE and
Ikegaki N: Implications of EPHB6, EFNB2, and EFNB3 expressions in
human neuroblastoma. Proc Natl Acad Sci USA. 97:10936–10941. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ikegaki N, Gotoh T, Kung B, Riceberg JS,
Kim DY, Zhao H, Rappaport EF, Hicks SL, Seeger RC and Tang XX: De
novo identification of MIZ-1 (ZBTB17) encoding a MYC-interacting
zinc-finger protein as a new favorable neuroblastoma gene. Clin
Cancer Res. 13:6001–6009. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Combaret V, Gross N, Lasset C, Frappaz D,
Peruisseau G, Philip T, Beck D and Favrot MC: Clinical relevance of
CD44 cell-surface expression and N-myc gene amplification in a
multicentric analysis of 121 pediatric neuroblastomas. J Clin
Oncol. 14:25–34. 1996.PubMed/NCBI
|
|
11
|
Nakagawara A, Arima-Nakagawara M, Scavarda
NJ, Azar CG, Cantor AB and Brodeur GM: Association between high
levels of expression of the TRK gene and favorable outcome in human
neuroblastoma. N Engl J Med. 328:847–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kogner P, Barbany G, Dominici C, Castello
MA, Raschella G and Persson H: Coexpression of messenger RNA for
TRK protooncogene and low affinity nerve growth factor receptor in
neuroblastoma with favorable prognosis. Cancer Res. 53:2044–2050.
1993.PubMed/NCBI
|
|
13
|
Suzuki T, Bogenmann E, Shimada H, Stram D
and Seeger RC: Lack of high-affinity nerve growth factor receptors
in aggressive neuroblastomas. J Nat Cancer Inst. 85:377–384. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tang XX, Robinson ME, Riceberg JS, Kim DY,
Kung B, Titus TB, Hayashi S, Flake AW, Carpentieri D and Ikegaki N:
Favorable neuroblastoma genes and molecular therapeutics of
neuroblastoma. Clin Cancer Res. 10:5837–5844. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ikegaki N, Bukovsky J and Kennett RH:
Identification and characterization of the NMYC gene product in
human neuroblastoma cells by monoclonal antibodies with defined
specificities. Proc Natl Acad Sci USA. 83:5929–5933. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Smets LA, Bout B and Wisse J: Cytotoxic
and antitumor effects of the norepinephrine analogue
meta-iodo-benzylguanidine (MIBG). Cancer Chemother Pharmacol.
21:9–13. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kung B, Zhao H, Hicks SL, Tang XX and
Ikegaki N: Biological significance of EPHA2 expression in
neuroblastoma. Int J Oncol. 35:845–850. 2009.
|
|
18
|
Schlessinger A, Geier E, Fan H, Irwin JJ,
Shoichet BK, Giacomini KM and Sali A: Structure-based discovery of
prescription drugs that interact with the norepinephrine
transporter, NET. Proc Natl Acad Sci USA. 108:15810–15815. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: a systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bodmer M, Meier C, Krahenbuhl S, Jick SS
and Meier CR: Long-term metformin use is associated with decreased
risk of breast cancer. Diabetes Care. 33:1304–1308. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wright JL and Stanford JL: Metformin use
and prostate cancer in Caucasian men: results from a
population-based case-control study. Cancer Causes Control.
20:1617–1622. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N,
Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated
protein kinase in mechanism of metformin action. J Clin Invest.
108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Warburg OH: Über den Stoffwechsel der
Tumoren. Springer; Berlin: 1926
|
|
24
|
Foretz M, Hebrard S, Leclerc J,
Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and
Viollet B: Metformin inhibits hepatic gluconeogenesis in mice
independently of the LKB1/AMPK pathway via a decrease in hepatic
energy state. J Clin Invest. 120:2355–2369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shackelford DB and Shaw RJ: The LKB1-AMPK
pathway: metabolism and growth control in tumour suppression. Nat
Rev Cancer. 9:563–575. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ben Sahra I, Regazzetti C, Robert G,
Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF,
Giorgetti-Peraldi S and Bost F: Metformin, independent of AMPK,
induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer
Res. 71:4366–4372. 2011.PubMed/NCBI
|
|
27
|
Weinhouse S: The Warburg hypothesis fifty
years later. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol.
87:115–126. 1976.PubMed/NCBI
|
|
28
|
Dang CV: Therapeutic targeting of
Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp
Quant Biol. 76:369–374. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sweeney D, Raymer ML and Lockwood TD:
Antidiabetic and antimalarial biguanide drugs are metal-interactive
antiproteolytic agents. Biochem Pharmacol. 66:663–677. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Owen MR, Doran E and Halestrap AP:
Evidence that metformin exerts its anti-diabetic effects through
inhibition of complex 1 of the mitochondrial respiratory chain.
Biochem J. 348:607–614. 2000. View Article : Google Scholar : PubMed/NCBI
|
